id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-N-0453-0045,FDA,FDA-2005-N-0453,"Letter from BASF SE (Morgan, Lewis & Bockius LLP)",Other,Letter(s),2015-10-15T04:00:00Z,2015,10,2015-10-15T04:00:00Z,,2015-10-15T14:41:58Z,,0,0,0900006481ccce50
FDA-2005-N-0453-0046,FDA,FDA-2005-N-0453,"Advice Letter from FDA CDER to Morgan, Lewis & Bockius LLP",Other,Letter(s),2015-10-15T04:00:00Z,2015,10,2015-10-15T04:00:00Z,,2015-10-15T14:42:13Z,,0,0,0900006481ccce52
FDA-2005-N-0453-0042,FDA,FDA-2005-N-0453,"Memorandum of Meeting Minutes between FDA CDER and BASF regarding Octyl Triazone and Bemotrizinol March 19, 2015",Other,Memorandum,2015-06-15T04:00:00Z,2015,6,2015-06-15T04:00:00Z,,2015-06-15T17:13:28Z,,0,0,0900006481b37e78
FDA-2005-N-0453-0043,FDA,FDA-2005-N-0453,"Memorandum of Meeting Minutes between FDA CDER and BASF Corporation regarding bisoctrizole March 20, 2015",Other,Memorandum,2015-06-15T04:00:00Z,2015,6,2015-06-15T04:00:00Z,,2015-06-15T17:13:48Z,,0,0,0900006481b37e79
FDA-2005-N-0453-0041,FDA,FDA-2005-N-0453,"Letter from FDA/CDER to Morgan, Lewis & Bockius, LLP (BASF SE) Granting Meeting Request Regarding GRASE Status of Octyl Triazone and Bemotrizinol",Other,Letter(s),2015-03-09T04:00:00Z,2015,3,2015-03-09T04:00:00Z,,2015-03-09T13:44:40Z,,0,0,0900006481a33de1
FDA-2005-N-0453-0040,FDA,FDA-2005-N-0453,"Letter from FDA/CDER to Morgan, Lewis & Bockius, LLP (BASF SE) Granting Meeting Request Regarding GRASE Status of Bisoctrizole",Other,Letter(s),2015-03-09T04:00:00Z,2015,3,2015-03-09T04:00:00Z,,2015-03-09T13:40:04Z,,0,0,0900006481a33ddd
FDA-2005-N-0453-0036,FDA,FDA-2005-N-0453,"Sunscreen Feedback Letters; Notice of Availability Under the Sunscreen
Innovation Act",Notice,Request for Comments,2015-01-07T05:00:00Z,2015,1,2015-01-07T05:00:00Z,2015-02-24T04:59:59Z,2015-02-24T03:08:50Z,2015-00002,0,0,09000064819a9732